BioNTech Rejects €20 Million Bid for Tübingen Site as Cancer Trial Stalls and Insider Sales Draw Scrutiny

BioNTech is discovering that the road from pandemic-era windfall to oncology mainstay is proving longer and rougher than shareholders once imagined. The Mainz-based company, which booked historic billion-euro profits during the COVID crisis, now finds itself navigating the statistical gauntlet of complex cancer trials while simultaneously dismantling the industrial capacity it built at breakneck speed.

A Clinical Setback in Head and Neck Cancer

The most recent jolt came from the Phase 2/3 AHEAD-MERIT study, where the combination of mRNA candidate BNT113 and pembrolizumab failed to achieve a statistically significant improvement in progression-free survival compared with pembrolizumab alone in patients with HPV16-positive head and neck cancer.

The trial is not being halted. According to Reuters and company statements, AHEAD-MERIT continues in order to evaluate overall survival as the second dual primary endpoint. Canaccord Genuity acknowledged as much on Wednesday, keeping its "Buy" rating on the stock intact while trimming its price target to $132 from $136. The analysts tied the adjustment to the interim analysis outcome but pointed to the ongoing overall survival assessment as a source of potential upside.

The miss serves as a sobering reminder that laboratory promise does not automatically translate into meaningful clinical benefit for patients.

Tübingen Sale Blocked, Plant Closures Staggered Through 2028

While the science plays out, management is reshaping its manufacturing base. BioNTech confirmed media reports that its German production sites in Idar-Oberstein, Marburg and Tübingen will close after no buyers emerged for the facilities.

A consortium of investors had submitted an offer of up to €20 million for the Tübingen plant, but the bid was contingent on more than €200 million in cash remaining in the facility. BioNTech deemed the proposal economically unviable and rejected it.

The retreat will unfold in stages: Tübingen is slated to shut down at the end of 2027, Marburg in early 2028 and Idar-Oberstein at the end of 2028. The phased wind-down marks a definitive end to the company's pandemic-era expansion infrastructure and forces a regime of strict cost discipline.

Insider Selling Under a Pre-Arranged Plan

Adding to the market's cautious mood, share sales by CEO Ugur Sahin have been registered. The transactions were executed under a trading plan established on June 3, 2026, pursuant to Rule 10b5-1. Through this mechanism, Sahin sold tranches of ordinary shares at prices ranging between $92.3142 and $97.2312, including blocks of 72,000 and 21,000 shares, with further disposals in the days that followed.

Such regulatory plans allow executives to automate securities sales well in advance, removing any suspicion of insider trading. Even so, in periods of clinical uncertainty, they tend to amplify psychological pressure on the share price.

Where the Stock Stands

The mixed picture has produced more guarded assessments on the Street. BioNTech shares closed yesterday at €80.45, up 1.2%. By Thursday the stock was holding at €80.40, a gain of 1.1%. The gap to the 52-week high remains substantial at 24%, reflecting persistent investor restraint.

For shareholders, the altered landscape demands a shift in perspective. The era of rapid share-price surges driven by government bulk orders is over. BioNTech is now squarely in the classic pharmaceutical cycle, where every advance must be paid for with lengthy study phases, setbacks and heavy development spending. The transformation is fully underway — and it asks investors above all for staying power.